Literature DB >> 8283893

Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting.

J G Coghlan1, W D Flitter, S M Clutton, R Panda, R Daly, G Wright, C D Ilsley, T F Slater.   

Abstract

In this prospective, randomized, double-blind, placebo-controlled study, the clinical, biochemical, and hemodynamic effects of xanthine oxidase inhibition in patients undergoing coronary artery bypass grafting were assessed. Allopurinol pretreatment significantly reduced the use of inotropic support after the operation (5 of 25 patients versus 13 of 25 patients, p < 0.01) and increased the rate of peripheral warming (11.4 +/- 0.85 hours versus 14.4 +/- 1 hours, p < 0.02). Twenty patients (9 in the allopurinol group and 11 in the placebo group) underwent invasive hemodynamic monitoring and intraoperative coronary sinus cannulation. The cardiac indexes of both groups were similar before the operation and for the first postoperative hour; thereafter, the cardiac index increased significantly in only the active treatment group (F = 3.33 and df = 5.90, p < 0.004). Products of lipid peroxidation (thiobarbituric acid reactive substances) increased significantly in only the placebo group, with increases being evident both in the systemic circulation (9.5 +/- 3.2 nmol/gm albumin, p < 0.007, and 24 +/- 5 nmol/gm albumin, p < 0.001, at 30 seconds and 2 minutes of reperfusion, respectively) and the coronary sinus (19.4 +/- 5.8 nmol/gm albumin, p < 0.004, and 28 +/- 4 nmol/gm albumin, p < 0.001, at 2 and 5 minutes of reperfusion, respectively. No significant difference was evident between the groups with respect to cardiac enzyme or vitamin E release. It is proposed that xanthine oxidase inhibition exerts its beneficial effects by reducing the level of free radical activity associated with reperfusion during coronary artery bypass grafting.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8283893

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  20 in total

1.  Pathobiology and Clinical Impact of Reperfusion Injury.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 2.  New uses for allopurinol.

Authors:  R O Day; D J Birkett; M Hicks; J O Miners; G G Graham; P M Brooks
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

3.  A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure.

Authors:  A M Shehab; R Butler; R J MacFadyen; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

4.  Relation between left ventricular function and oxidative stress in patients undergoing bypass surgery.

Authors:  E De Vecchi; M G Pala; G Di Credico; V Agape; G Paolini; P A Bonini; A Grossi; R Paroni
Journal:  Heart       Date:  1998-03       Impact factor: 5.994

Review 5.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

Review 6.  Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.

Authors:  Arvind Bhimaraj; W H Wilson Tang
Journal:  Heart Fail Clin       Date:  2011-10-22       Impact factor: 3.179

Review 7.  Therapy for myocardial stunning.

Authors:  Y Birnbaum; R A Kloner
Journal:  Basic Res Cardiol       Date:  1995 Jul-Aug       Impact factor: 17.165

Review 8.  Myocardial viability.

Authors:  Y Birnbaum; R A Kloner
Journal:  West J Med       Date:  1996-12

9.  Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?

Authors:  W Doehner; S D Anker
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

Review 10.  Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.

Authors:  Zoltan Ungvári; Sachin A Gupte; Fabio A Recchia; Sándor Bátkai; Pál Pacher
Journal:  Curr Vasc Pharmacol       Date:  2005-07       Impact factor: 2.719

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.